AXS25 DigitalGuide V2 04.18 pages - Flipbook - Page 25
Our priorities
Everyone at GSK is focused on our three long-term priorities:
Innovation
We develop and launch
new medicines and vaccines
where they are needed, with
better, faster and smarter R&D.
Performance
Driven by our innovation, we
have delivered consistent sales
and profit growth and improved
our long-term outlooks.
Trust
We focus on issues that matter most
to our business, our stakeholders, and
society, and where we can have the
greatest impact.
19
£31.4bn
2nd
pipeline assets
in phase III/ registration
medicines and vaccine sales
in the Access to Medicine Index
12
2.1bn
91%
new collaborations
and acquisitions
packs of medicines and
vaccine doses delivered
of our Responsible Business
Performance Rating metrics
‘met’ or ‘exceeded’
In 2024:
Our culture
We have almost 70,000 people in 75 countries worldwide
and culture at GSK is something we all own.
We are ambitious for patients
to deliver what matters better
and faster.
We are accountable for impact
with clear ownership and support
to succeed.
We do the right thing with integrity
and care because people count
on us.
Why we do it
This powers our purpose, drives
delivery of our strategy and helps
make GSK a place where people
can thrive.
These are the foundations for
how, together, we’ll deliver more
for our patients, shareholders
and GSK people.
We aim to get ahead of disease together –
to positively impact the health of 2.5 billion
people by the end of the decade.
